Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

NCT00019084 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-20

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for advanced cancer.

PURPOSE: Phase II trial to study the effectiveness of a vaccine made with the patients' white blood cells mixed with tumor proteins in treating patients who have advanced cancer.

Conditions

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: mutant p53 peptide pulsed dendritic cell vaccine
BIOLOGICAL: ras peptide cancer vaccine
BIOLOGICAL: sargramostim
BIOLOGICAL: therapeutic autologous lymphocytes
BIOLOGICAL: therapeutic tumor infiltrating lymphocytes

Sponsors & Collaborators

National Cancer Institute (NCI)
lead NIH

Principal Investigators

Samir N. Khleif, MD · National Cancer Institute (NCI)

Study Design

Purpose: TREATMENT

Eligibility

Min Age: 18 Years
Sex: ALL
Healthy Volunteers: No

Timeline & Regulatory

Start: 1996-02-29
Completion: 2003-05-31

Countries

United States

Study Locations

More Related Trials

Entities

Diseases